Press release: invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal
Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment-refractory solid tumors Decentralized point-of-care manufacturing of APN401 was feasible across manufacturing sites APN401 demonstrated a...
October 15, 2026
No Comments
Meet invIOs’s new Scientific Advisory Board
Today we're unveiling our new Scientific Advisory Board (SAB), which brings together five leading European cancer experts to help fast-forward our growth. The SAB is a multi-disciplinary formation with cross-cutting knowledge...
February 24, 2023
No Comments
Clinical trials: From bench to bedside to improve outcomes for cancer patients
Clinical trials are crucial to understanding how drugs and therapies work, how safe they are in humans, and how effective they are in treating cancer. They are vital for making...
January 18, 2023
No Comments
